Twist Bioscience reports Q1 EPS (75c), consensus (78c)

Reports Q1 revenue $71.5M, consensus $67.58M. Total orders received for the first quarter increased to $77.5M compared to $64.7M for the same period of fiscal 2023. “We’re starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%,” said Emily Leproust, CEO and co-founder of Twist Bioscience. “In SynBio, after a limited launch of Express Genes in November, we expanded the offering to include midi and Maxi preps at Express speed and over time, we expect this offering will allow us to both expand our share of market and convert the Maker’s Market of researchers who make their own genes into DNA buyers.”